Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 1, 2015Thrombosis and Haemostasis

HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi

View Full Paper
Ask AI
Bookmark
Share

Population

Human platelets, human coronary artery thrombi, and blood from wild-type C57Bl6, TLR4-/-, and RAGE-/- mice

Comparison

Recombinant HMGB1 and thrombin-induced platelet… vs Unactivated platelets and RAGE-/- mouse platelets

Design

Preclinical

Authors

MBMichael F. BodeDHDavid HaenelCHChristoph E. Hagemeyer

Discussion

Loading...

Member takes

Overview

HMGB1-RAGE platelet binding is not clinically actionable; extends animal data but leaves open therapeutic targeting in atherothrombosis.

Structured PICO

P
Population
Human platelets, human coronary artery thrombi, and blood from wild-type C57Bl6, TLR4-/-, and RAGE-/- mice
I
Intervention
Recombinant HMGB1 and thrombin-induced platelet activation
C
Comparator
Unactivated platelets and RAGE-/- mouse platelets
O
Outcome
Binding of HMGB1 to platelets and RAGE expressionsurrogate

HMGB1 binds to activated platelets via the RAGE receptor and is highly expressed in human coronary artery thrombi, suggesting a potential target for anti-inflammatory therapies in atherothrombosis.

Cite This Study

Bode et al. (2015) studied this question.

synapsesocial.com/papers/6a7118b3660549caf2c5bbcehttps://doi.org/10.1160/th14-12-1073
View Full Paper
Ask AI
Bookmark
Share